OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET. The call will be hosted by AIM’s Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 ...

OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy in conjunction with the chemotherapy drug paclitaxel in the treatment of early stage, triple-negativ ...

OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing that combination dendritic cell-based vaccines including anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model. “Therapeutic Anti-Tumor E ...

OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET. As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the e ...

OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET. As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. ...

OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET. As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. ...

OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregistered ...

OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences. Details for the presentations are as follows: Event: Healthcare Company Showcase hosted by Alliance Global PartnersDate and Time: Tuesday, May 21, 2024, at 3:20 PM ETWebcast Link Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarDate and Time: Wednesday, May 22 ...

OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences. Details for the presentations are as follows: Event: Healthcare Company Showcase hosted by Alliance Global PartnersDate and Time: Tuesday, May 21, 2024, at 3:20 PM ETWebcast Link Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarDate and Time: Wednesd ...

财务数据和关键指标变化 - 公司在第一季度末拥有10.9亿美元现金 [26] - 研发费用保持稳定,而一般及管理费用较去年同期有所上升 [26] - 公司认为现有现金可以支持公司运营并达到多个潜在价值驱动的里程碑 [26] 各条业务线数据和关键指标变化 - 在DURIPANC联合用药试验中,Ampligen和durvalumab的组合治疗在第一剂量水平的安全性评估中表现良好,未出现严重不良事件或剂量限制性毒性 [8] - 在复发性卵巢癌联合用药试验中,Ampligen与pembrolizumab的组合疗法显示出强大的协同效果,客观缓解率达45%,远高于pembrolizumab单药的8%[20][21][22] - 公司正在等待AMP-518试验探索性生物标志物分析的结果,以确定下一步针对COVID-19后遗症疲劳的临床试验方案 [23][24] 各个市场数据和关键指标变化 - 未提及 公司战略和发展方向及行业竞争 - 公司认为Ampligen作为联合用药具有广谱适用于多种实体瘤的潜力,正在与制药公司洽谈商业化合作 [28][29][56][57] - 公司已获得Ampligen与PD-L1检查点抑制剂联合用药的协同疗效的专利保护 [59] - 公司正在优化Ampligen的制造工艺,以提高成本效率,为未来大规模临床试验和商业化做准备 [63][65][66] 管理层对经营环境和未来前景的评论 - 公司对Ampligen在多个适应症的临床数据持乐观态度,认为可以为患者提供有意义的治疗解决方案 [28][29][30] - 公司相信未来会有更多积极的安全性和疗效数据,有助于与潜在商业合作伙伴的洽谈 [29] 问答环节重要的提问和回答 问题1 **Unidentified Participant 提问** 询问复发性卵巢癌联合用药试验的患者人数和下一步计划 [33][34][35][36][37][38] **Thomas Equels 和 Christopher McAleer 回答** - 目前有21名患者纳入评估,这是一个中期报告,后续还会有更多患者入组 [35][37] - 这一数据显示Ampligen与化疗和免疫检查点抑制剂的联合疗法具有强大的协同作用,公司将利用这些数据推进商业化合作 [43][45] 问题2 **James Molloy 提问** 询问其他在研适应症的临床进展及商业化合作计划 [49][50][51][52][53][54][55][56][57][58][59][60] **Thomas Equels 回答** - 公司正在与制药公司合作开展多个联合用药临床试验,这些数据有助于降低大规模临床试验的风险 [50][51][52][56][57][58][59] - 公司已聘请专业的商业开发团队,正在与潜在合作伙伴接洽,希望利用这些临床数据推进商业化合作 [56][57][58][59] 问题3 **Ed Woo 提问** 询问Ampligen最新一批生产的情况,以及未来生产计划 [62][63][64][65][66] **Thomas Equels 回答** - 最新一批Ampligen生产顺利,成本有所上升但是可控 [63] - 未来两年内公司可能不需要再生产新批次,但如果启动大规模临床试验,则需要增加产能 [65][66] - 公司正在优化Ampligen的生产工艺,以提高效率和降低成本 [66]